99 related articles for article (PubMed ID: 3162451)
1. Immunotherapy of pancreatic cancer with monoclonal antibody BW 494.
Schulz G; Büchler M; Muhrer KH; Klapdor R; Kübel R; Harthus HP; Madry N; Bosslet K
Int J Cancer Suppl; 1988; 2():89-94. PubMed ID: 3162451
[TBL] [Abstract][Full Text] [Related]
2. [Monoclonal antibodies in the therapy of non-resectable pancreatic cancers. Initial experiences].
Muhrer KH; Büchler M; Lucks A; Süss D; Klapdor R; Schulz G
Chirurg; 1988 May; 59(5):328-34. PubMed ID: 3396446
[TBL] [Abstract][Full Text] [Related]
3. Anti-idiotypic antibodies to monoclonal antibody CO17-1A.
Herlyn D; Sears H; Iliopoulos D; Lubeck M; Douillard JY; Sindelar W; Tempero M; Mellstedt H; Maher M; Koprowski H
Hybridoma; 1986 Jul; 5 Suppl 1():S51-8. PubMed ID: 3488951
[TBL] [Abstract][Full Text] [Related]
4. [Immunotherapy of advanced pancreatic carcinoma with the monoclonal antibody BW 494].
Büchler M; Kübel R; Malfertheiner P; Friess H; Schulz G; Bosslet K; Beger HG
Dtsch Med Wochenschr; 1988 Mar; 113(10):374-80. PubMed ID: 3349938
[TBL] [Abstract][Full Text] [Related]
5. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy with monoclonal antibody (Mab) in pancreatic adenocarcinoma.
Tempero MA; Haga Y; Sivinski C; Steplewski Z; Kay HD; Pour P
Int J Pancreatol; 1991; 9():125-34. PubMed ID: 1744438
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulating IL-6 activity by murine monoclonal antibodies.
Brochier J; Legouffe E; Liautard J; Gaillard JP; Mao LQ; Bataille R; Rossi JF; Klein B
Int J Immunopharmacol; 1995 Jan; 17(1):41-8. PubMed ID: 7782152
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer.
Goodman GE; Hellström I; Brodzinsky L; Nicaise C; Kulander B; Hummel D; Hellström KE
J Clin Oncol; 1990 Jun; 8(6):1083-92. PubMed ID: 2161448
[TBL] [Abstract][Full Text] [Related]
9. Phase II multicenter evaluation of prolonged murine monoclonal antibody 17-1A therapy in pancreatic carcinoma.
Weiner LM; Harvey E; Padavic-Shaller K; Willson JK; Walsh C; LaCreta F; Khazaeli MB; Kirkwood JM; Haller DG
J Immunother Emphasis Tumor Immunol; 1993 Feb; 13(2):110-6. PubMed ID: 8318495
[TBL] [Abstract][Full Text] [Related]
10. Human monoclonal anti-idiotypic antibodies as an epitope vaccine against pancreatic carcinoma.
Bosslet K; Büchler M; Klapdor R; Muhrer C; Sedlacek HH; Schulz G
Behring Inst Mitt; 1988 Apr; (82):193-6. PubMed ID: 3261582
[TBL] [Abstract][Full Text] [Related]
11. [Therapy of pancreatic carcinoma with the monoclonal antibody BW 494/32: first clinical results].
Friess H; Büchler M; Schulz G; Beger HG
Immun Infekt; 1989 Feb; 17(1):24-6. PubMed ID: 2925220
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of interferon gamma and monoclonal antibody 17-1A in pancreatic cancer: biologic and clinical effects.
Tempero MA; Sivinski C; Steplewski Z; Harvey E; Klassen L; Kay HD
J Clin Oncol; 1990 Dec; 8(12):2019-26. PubMed ID: 2121912
[TBL] [Abstract][Full Text] [Related]
13. Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer.
Giantonio BJ; Alpaugh RK; Schultz J; McAleer C; Newton DW; Shannon B; Guedez Y; Kotb M; Vitek L; Persson R; Gunnarsson PO; Kalland T; Dohlsten M; Persson B; Weiner LM
J Clin Oncol; 1997 May; 15(5):1994-2007. PubMed ID: 9164211
[TBL] [Abstract][Full Text] [Related]
14. Percolation and binding of MAB BW 494 to pancreatic carcinoma tissues during high dose immunotherapy and consequences for future therapy modalities.
Bosslet K; Keweloh HC; Hermentin P; Muhrer KH; Sedlacek HH; Schulz G
Behring Inst Mitt; 1990 Dec; (87):68-75. PubMed ID: 2096821
[TBL] [Abstract][Full Text] [Related]
15. The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A.
Gruber R; van Haarlem LJ; Warnaar SO; Holz E; Riethmüller G
Cancer Res; 2000 Apr; 60(7):1921-6. PubMed ID: 10766181
[TBL] [Abstract][Full Text] [Related]
16. Immunological tailoring of monoclonal antibodies for immunotherapy of pancreatic carcinoma.
Bosslet K; Döring N; Seemann G; Schulz G; Sedlacek HH
Int J Cancer Suppl; 1988; 2():85-8. PubMed ID: 3162450
[TBL] [Abstract][Full Text] [Related]
17. Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival.
Miotti S; Negri DR; Valota O; Calabrese M; Bolhuis RL; Gratama JW; Colnaghi MI; Canevari S
Int J Cancer; 1999 Feb; 84(1):62-8. PubMed ID: 9988234
[TBL] [Abstract][Full Text] [Related]
18. A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer.
Büchler M; Friess H; Schultheiss KH; Gebhardt C; Kübel R; Muhrer KH; Winkelmann M; Wagener T; Klapdor R; Kaul M
Cancer; 1991 Oct; 68(7):1507-12. PubMed ID: 1654194
[TBL] [Abstract][Full Text] [Related]
19. Specific detection of anti-idiotypic immune responses in cancer patients treated with murine monoclonal antibody.
Herlyn D; Lubeck M; Sears H; Koprowski H
J Immunol Methods; 1985 Dec; 85(1):27-38. PubMed ID: 3878375
[TBL] [Abstract][Full Text] [Related]
20. The clinical significance of HAMA in patients treated with mouse monoclonal antibodies.
Frödin JE; Lefvert AK; Mellstedt H
Cell Biophys; 1992; 21(1-3):153-65. PubMed ID: 1285327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
